Mantle Cell Lymphoma Clinical Trials

A listing of Mantle Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 144 clinical trials
featured
Newly Diagnosed Mantle Cell Lymphoma who are not eligible for a bone marrow transplant.

Newly Diagnosed Mantle Cell Lymphoma who are not eligible for a bone marrow transplant.

  • 834 views
  • 08 Nov, 2020
  • 1 location
featured
A Study of the Kinetics of Lymphoid Cells in Patients with Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers

Background: Chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL) are types of cancers in which there are too many

lymphocytosis
chronic lymphocytic leukemia
cancer
lymphoma
mantle cell lymphoma
  • 102 views
  • 15 Apr, 2019
  • 1 location
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare LOXO-305 to other drugs that work in a similar way that have

  • 0 views
  • 13 Jun, 2021
  • 64 locations
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell

bendamustine
acalabrutinib
rituximab
cyclin d1
  • 1270 views
  • 15 May, 2021
  • 246 locations
Venetoclax Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of rituximab-lenalidomide in patients with relapsed/refractory MCL.

  • 3 views
  • 26 Jan, 2021
  • 22 locations
Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

The primary objective is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL) in Cohort 3 of this study.

  • 0 views
  • 16 May, 2021
  • 31 locations
Rituximab Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

Prospective, multicenter, phase II trial designed to evaluate whether the addition of Venetoclax after rituximab, bendamustine and cytarabine (R-BAC) to high risk patients with mantle cell

bendamustine
hepatitis b core antibody
hepatitis b surface antigen
high dose chemotherapy
cyclin d1
  • 14 views
  • 25 Mar, 2021
  • 49 locations
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

plus rituximab followed by standard PBSCT (dexamethasone, carmustine, cytarabine, etoposide, and melphalan [Dexa-BEAM]/TBI/high dose cyclophosphamide) in patients with untreated mantle cell

measurable disease
high dose chemotherapy
rituximab
cell transplantation
r-chop
  • 134 views
  • 07 Nov, 2020
  • 2 locations
Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma

refractory Mantle Cell Lymphoma (MCL) or who had sub-optimal response to standard therapy in the presence of TP53 mutation.

btk inhibitor
direct bilirubin
refractory mantle cell lymphoma
neutrophil count
stem cell transplantation
  • 0 views
  • 24 Jan, 2021
  • 1 location
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

bendamustine
tumor burden
neutrophil count
platelet count
rituximab
  • 37 views
  • 26 Mar, 2021
  • 37 locations